These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs]. Seigneurie AS; Sauvanaud F; Limosin F Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134 [TBL] [Abstract][Full Text] [Related]
3. Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. Meyer JM CNS Spectr; 2016 Dec; 21(S1):13-24. PubMed ID: 28044943 [TBL] [Abstract][Full Text] [Related]
4. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Niemann N; Jankovic J Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342 [TBL] [Abstract][Full Text] [Related]
7. [Late-Onset Dyskinesia Occurring During Antipsychotic Treatment for Schizophrenia: Management of Tardive Dyskinesia Based on the Latest Knowledge]. Sakata M; Ito H Brain Nerve; 2022 May; 74(5):571-574. PubMed ID: 35589649 [TBL] [Abstract][Full Text] [Related]
8. [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 1 : Dystonia, akathisia und parkinsonism]. Hirjak D; Kubera KM; Bienentreu S; Thomann PA; Wolf RC Nervenarzt; 2019 Jan; 90(1):1-11. PubMed ID: 30128734 [TBL] [Abstract][Full Text] [Related]
9. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. Carbon M; Hsieh CH; Kane JM; Correll CU J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614 [TBL] [Abstract][Full Text] [Related]
10. Antipsychotic-induced tardive dyskinesia: update on epidemiology and management. Widschwendter CG; Hofer A Curr Opin Psychiatry; 2019 May; 32(3):179-184. PubMed ID: 30720484 [TBL] [Abstract][Full Text] [Related]
11. Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review. Artukoglu BB; Li F; Szejko N; Bloch MH J Clin Psychiatry; 2020 May; 81(4):. PubMed ID: 32459404 [TBL] [Abstract][Full Text] [Related]
12. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis. Mentzel TQ; van der Snoek R; Lieverse R; Oorschot M; Viechtbauer W; Bloemen O; van Harten PN J Clin Psychiatry; 2018 Sep; 79(6):. PubMed ID: 30257080 [TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management. Salem H; Pigott T; Zhang XY; Zeni CP; Teixeira AL Expert Rev Neurother; 2017 Sep; 17(9):883-894. PubMed ID: 28750568 [TBL] [Abstract][Full Text] [Related]
15. Implications of Antipsychotic Use: Antipsychotic-Induced Movement Disorders, with a Focus on Tardive Dyskinesia. Dilks S; Xavier RM; Kelly C; Johnson J Nurs Clin North Am; 2019 Dec; 54(4):595-608. PubMed ID: 31703784 [TBL] [Abstract][Full Text] [Related]